Presence of protein marks toxicity in leukemia
the ONA take:
A recent study examined the protein inositol polyphosphate 4-phosphatase II (INPP4B) in patients that had been diagnosed with acute myeloid leukemia.
When examined, the data indicated that the presence of this protein indicates a likely toxicity effect associated with chemotherapy.
Chemotherapy is a standard clinic treatment for this disease, but patients can now be screened for inositol polyphosphate 4-phosphatase II and recommended for other treatments less likely to be toxic as needed.
The researchers hope to explore exactly how the protein behaves in cancer cells, specifically related to chemoresistance, so the protein and pathway may one day be effectively targeted.
This research was led by PhD student Sewa Rijal from the Faculty of Medicine, Nursing and Health Sciences (FMNHS), under the supervision of Professor Andrew Wei and Professor Christina Mitchell, Dean of FMNHS. Findings were published in the journal Blood.
Presence of this protein indicates a likely toxicity effect associated with chemotherapy.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|